Sheri Dubey

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay
    Sheri Dubey
    Department of Vaccine and Biologics Research, Merck Research Laboratories, West Point, PA 19486, USA
    J Acquir Immune Defic Syndr 45:20-7. 2007
  2. ncbi Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC
    Lisa S Kierstead
    Vaccine and Biologics Research, Merck Research Laboratories, West Point and Wayne, PA 19087, USA
    AIDS Res Hum Retroviruses 23:86-92. 2007
  3. ncbi Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 77:6305-13. 2003
  4. ncbi Intracellular staining for HIV-specific IFN-gamma production: statistical analyses establish reproducibility and criteria for distinguishing positive responses
    Wendy L Trigona
    Department of Viral Vaccine Research, Merck Research Laboratories, West Point, PA 19486, USA
    J Interferon Cytokine Res 23:369-77. 2003
  5. ncbi Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge
    Danilo R Casimiro
    Department of Vaccines Basic Research, Merck Research Laboratories, Merck and Co, West Point, Pennsylvania 19486, USA
    J Virol 84:2996-3003. 2010
  6. ncbi Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene
    Danilo R Casimiro
    Department of Virus and Cell Biology, Merck Research Laboratories, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 76:185-94. 2002
  7. ncbi Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)
    Sylvia Janetzki
    ZellNet Consulting, Inc, Fort Lee, NJ, USA
    Cancer Immunol Immunother 57:303-15. 2008

Detail Information

Publications7

  1. ncbi Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay
    Sheri Dubey
    Department of Vaccine and Biologics Research, Merck Research Laboratories, West Point, PA 19486, USA
    J Acquir Immune Defic Syndr 45:20-7. 2007
    ....
  2. ncbi Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC
    Lisa S Kierstead
    Vaccine and Biologics Research, Merck Research Laboratories, West Point and Wayne, PA 19087, USA
    AIDS Res Hum Retroviruses 23:86-92. 2007
    ..These studies establish the importance of optimal conditions for PBMC collection and handling to the success of a clinical development program...
  3. ncbi Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 77:6305-13. 2003
    ....
  4. ncbi Intracellular staining for HIV-specific IFN-gamma production: statistical analyses establish reproducibility and criteria for distinguishing positive responses
    Wendy L Trigona
    Department of Viral Vaccine Research, Merck Research Laboratories, West Point, PA 19486, USA
    J Interferon Cytokine Res 23:369-77. 2003
    ..Using these statistical criteria, the ICS assay is sufficiently robust for use in HIV-specific vaccine trials...
  5. ncbi Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge
    Danilo R Casimiro
    Department of Vaccines Basic Research, Merck Research Laboratories, Merck and Co, West Point, Pennsylvania 19486, USA
    J Virol 84:2996-3003. 2010
    ..The implications of these results in light of the recent discouraging results of the phase IIb study of the trivalent Ad5 HIV-1 vaccine are discussed...
  6. ncbi Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene
    Danilo R Casimiro
    Department of Virus and Cell Biology, Merck Research Laboratories, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 76:185-94. 2002
    ..Thus, optimizing the immunogenic properties of HIV-1 Pol at the level of the gene sequence validates it as an antigen and provides an important step toward the construction of a potent pol-based HIV-1 vaccine component...
  7. ncbi Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)
    Sylvia Janetzki
    ZellNet Consulting, Inc, Fort Lee, NJ, USA
    Cancer Immunol Immunother 57:303-15. 2008
    ..These results provide initial harmonization guidelines to optimize Elispot assay performance to the immunotherapy community. Further optimization is in process with ongoing panels...